Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.

Also called NCT03760991

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 372 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03760991
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina, Colombia, Egypt, Hong Kong SAR China, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03760991. Allocation not applicable; no masking; primary purpose treatment. Start 2018-12-18 (actual); primary completion 2020-09-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
Acronym
ARTEMIS-DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE (U300)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03760991
Content hash
6f1caef8c4580dce8d9d7f2a1f6807500afc56f8cafb3f10842dcf3e8ff9d0c4